Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment
C. Leigh Moyer(Johns Hopkins University), Phuoc T. Tran(University of Chicago Medical Center), Matthew P. Deek(Johnson University), Jean L. Wright(University of North Carolina at Chapel Hill), Ryan Phillips, Mario A. Eisenberger(Johns Hopkins University), Edward M. Schaeffer(Northwestern University), Emmanuel S. Antonarakis(University of Minnesota), Ashley E. Ross(St. Jude Children's Research Hospital), Daniel Y. Song(Johns Hopkins University), Curtiland Deville(Johns Hopkins University), Diane K. Reyes(Johns Hopkins University), Stephanie A. Terezakis(Johns Hopkins University), Noura Radwan(Johns Hopkins University), Kenneth J. Pienta(Johns Hopkins University), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Patrick C. Walsh(Johns Hopkins University), Theodore L. DeWeese(Johns Hopkins University)
Cited by 30
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k